FN1 and neoplasm: EDB-target therapy has been explored in solid tumors and hematological malignancies using either Radretumab (NCT01242943; NCT01124812; NCT01125085) or antibody–cytokine fusion proteins (L19-IL2, Darleukin and L19-TNF, Fibromun) on the tumor site by homing to the EDB-FN.